The Medical Treatment of Metastatic Breast Cancer

Breast cancer is a worldwide physical condition load through over one million novel cases identified universal and over than 250,000 novel cases identified in U.S. each year.  The early stage of the disease without a prior diagnosis 2 Metastatic Breast Cancer (MBC), with approximately one-third of women, despite the locoregional therapy and adjuvant chemotherapy, fur thermore United States.2 all new breast cancer represents approximately 5% of early stage breast cancer will experience a distant relapse. As a result, the United States, more than 40,000 deaths each year are related to breast cancer. MBC associ-ated median survival of only 2 to 3 years of treatment is a likely outcome, investigators disease specific optimization results, ideally, prevent or relieve symptoms associated with cancer and quality of life by try to improve results. The most important of these efforts, scheduling, recent therapeutic innovations in drug delivery, resulting in a large number, and targeted therapy. INNO-vations of the current speed of their treatment, however, grown ingly complex clinical decision is made. Strategy has not been determined, although ideal, several general management Ment MBC rationale for the strategy will be reviewed here.

Improved survival in MBC
Within the past 2 decades, MBC management eg taxanes, vinorelbine (Navelbine, GlaxoSmithKline), gemcitabine (Gemzar, Lilly), and capecitabine (Xeloda, ROCHE's) with the introduction of new systemic agents have been developed, the third generation of aromatase inhibitors (ALS), including the new hormonal agents and trastuzumab (Herceptin, a Genentech), bevacizumab (Avastin, a Genentech), and lapatinib (Tykerb, GlaxoSmithKline) including biological treatment. MBC during the past few decades, improvements in survival have been described, although these improvements can be attributed directly to innovation thyra- peutic 3 • 4 held in British Columbia only conclusive evidence of a large population-based retro-spective analysis is from. 5 MBC investigators aged 75 or younger at the time of diagnosis to treatment for women with results reported by far. The cohort of women diagnosed between 1991 and 1992 in the median survival of 14.3 months, compared with a small profit from 1994 to 1995 of paclitaxel and vinorelbine Introduction- duction, docetaxel 18.5 months with the introduction of further improvements from 1997 to 1998, and was celebrated with ALS, and 2001 (Table 1) in 1999 with the introduction of capecitabine and trastuzumab is a significant improvement of 21.7 months. However, treatment of MBC INNO-vation and improvement in survival, methodologic limitations of a retrospective analysis of all subgroups benefited from these innovations is the possibility that the relationship between the opti wealth management paradigm MBC is an ongoing controversy about has resulted. Principles of treatment of women with MBC MBC a consensus algorithm for the management, administration appropriately MBC Ment strategy a number of patient and tumor characteristics (Figure 1) can be determined by considering.  more >>